Crescent Diagnostics, the company behind a new test to predict osteoporosis, has raised €1.5 million in Series A funding.
The funding round was a syndicated deal between Bank of Ireland Seed Fund, managed by Kernel Capital, AIB Seed Capital Fund, co-managed by Enterprise Equity Venture Capital, and existing venture investor Seroba BioVentures.
It will be used to run additional clinical trials on Crescent’s BTQ test, which was developed at the University of Limerick to enable...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team